Gilead Sciences Soars on “Striking” Clinical Trial Data
On Thursday after the closing bell, Gilead Sciences (NASDAQ: GILD ) released its Q4 earnings results. While the biotech giant missed analysts earnings estimates, sales numbers for the quarter came in slightly higher than projected. More importantly, Gilead management announced positive clinical da…
Read the rest of this article on Perspectives Content Submission
Our Products
Services
Upcoming Events
Conferences
-
Morningstar Investment Conference
June 12-14, 2013
Chicago, IL
Conference hashtag: #MIC25 -
Morningstar ETF Invest Conference
Oct. 2-4, 2013
Chicago, IL
Conference hashtag: #ETFInvest
Webinars
-
Real Assets to the Rescue
Tuesday, April 9
11:00 a.m. ET | 10:00 a.m. CT -
The Hunt for Income
Tuesday, January 29
11:00 a.m. ET | 10:00 a.m. CT -
Introduction to ETF Managed Portfolios
Monday, December 10
4:00 p.m. ET | 3:00 p.m. CT -
Using ETFs for Income
Aired on Tuesday, June 12 - Archive
